NEWMONT Corp /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEWMONT Corp /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $6.71B | Feb 21, 2017 |
| FY2016 | Dec 31, 2015 | $6.09B | Feb 21, 2017 |
| FY2016 | Dec 31, 2014 | $6.82B | Feb 21, 2017 |
| FY2015 | Dec 31, 2013 | $8.41B | Feb 17, 2016 |
| FY2014 | Dec 31, 2012 | $9.96B | Feb 20, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.67B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $18.68B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $11.81B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $11.92B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $12.22B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $11.50B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $2.97B | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $2.71B | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $2.26B | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $1.80B | Feb 20, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $780.00M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $711.00M | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $331.00M | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $483.00M | Feb 20, 2020 |
| FY2019 | Dec 31, 2018 | $541.00M | Feb 20, 2020 |
| FY2019 | Sep 30, 2018 | $401.00M | Feb 20, 2020 |
| FY2019 | Jun 30, 2018 | $381.00M | Feb 20, 2020 |
| FY2019 | Mar 31, 2018 | $459.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $465.00M | Feb 21, 2019 |
| FY2018 | Sep 30, 2017 | $472.00M | Feb 21, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.09B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.35B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($2.49B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($429.00M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.17B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.83B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $565.00M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $2.18B | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | ($25.00M) | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $87.00M | Feb 20, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $197.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $200.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $229.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $154.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $122.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $150.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $153.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $143.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $134.00M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.33B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.76B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.22B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.28B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $4.88B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.87B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.83B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $2.12B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $2.79B | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.12B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $56.35B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $55.51B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $38.48B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $40.56B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $41.37B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $39.97B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $20.72B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $20.65B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $21.07B | Feb 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.08B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $26.24B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $26.30B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $18.95B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.70B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $17.49B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $17.56B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $9.20B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $9.13B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $9.16B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.87B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $29.93B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $29.03B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $19.35B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $22.02B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $23.01B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $21.42B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $10.50B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $10.54B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $10.72B | Feb 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.66B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.66B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.00B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.97B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $2.77B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.77B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.67B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $58.00M | Feb 18, 2021 |
| FY2015 | Dec 31, 2015 | $58.00M | Feb 17, 2016 |
| FY2015 | Dec 31, 2014 | $105.00M | Feb 17, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.43B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($1.32B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($3.00B) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $916.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.10B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.00B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.29B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $383.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $410.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $716.00M | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.65B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.62B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.00B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.88B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.99B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.54B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.24B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.40B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $3.26B | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $2.76B | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12B | Feb 19, 2026 |
| FY2024 | Dec 31, 2024 | $8.48B | Feb 21, 2025 |
| FY2023 | Dec 31, 2023 | $8.87B | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $5.57B | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $5.71B | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $6.08B | Feb 18, 2021 |
| FY2019 | Dec 31, 2019 | $6.17B | Feb 20, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | 2 | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 20, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | 2 | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 20, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.09B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 1.13B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 1.15B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 793.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 792.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 800.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 808.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 533.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 533.00M | Feb 21, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.42B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.75B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.76B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $834.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $889.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $301.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $134.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $67.00M | Feb 21, 2019 |